Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS | PLOS ONE
![Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. | Semantic Scholar Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fc8073074af9c50576c23cf71f14d56e2ae1ba82/6-Figure3-1.png)
Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. | Semantic Scholar
![Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study | Scientific Reports Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-018-21884-y/MediaObjects/41598_2018_21884_Fig1_HTML.jpg)
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study | Scientific Reports
![Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction - ScienceDirect Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0735109717370067-gr5.jpg)
Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction - ScienceDirect
CorConsult Rx - #Repost @ambcarerx ・・・ Oral Anticoagulants have many chronic indications, most commonly VTE treatment/prophylaxis, atrial fibrillation, and valvular heart disease. VTE & AF can both be treated with either warfarin
![Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants | Journal of the American College of Cardiology Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants | Journal of the American College of Cardiology](https://www.jacc.org/cms/asset/318ce34f-9d46-40b0-a6b1-4db9d39915c9/fx1.jpg)
Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants | Journal of the American College of Cardiology
![JCM | Free Full-Text | Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO) JCM | Free Full-Text | Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)](https://www.mdpi.com/jcm/jcm-10-04185/article_deploy/html/images/jcm-10-04185-g001.png)
JCM | Free Full-Text | Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)
![The New Oral Anticoagulants in Atrial Fibrillation: Once or Twice Daily? - American College of Cardiology The New Oral Anticoagulants in Atrial Fibrillation: Once or Twice Daily? - American College of Cardiology](https://www.acc.org/-/media/Non-Clinical/Migration-Content/Hot-Topics/Anticoagulation-Management/The-New-Oral-Anticoagulants-in-Atrial-Fibrillation-Once-or-Twice-Daily/AM_HotTopic_Dec13_Table1.gif?la=en&hash=CDD5776702B830B601B0A7851CB554A1B900CBA6)